Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by C. O' Regan
PIN50 the Clinical Efficacy and Cost-Effectiveness of Boceprevir in Combination With Pegylated Interferon- Alfa and Ribavirin for the Treatment of Genotype 1 Chronic Hepatitis C Patients: A Within Trial Analysis From the Perspective of the Scottish National Health Service (NHS)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
PGI18 Cost-Effectiveness of Boceprevir in Combination With Pegylated Interferon Alfa and Ribavirin for the Treatment of Genotype 1 Chronic Hepatitis C: Submission to the National Institute for Health and Clinical Excellence (NICE)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Safety and Efficacy of Pegylated Interferon Alpha-2a and Ribavirin Combination in Treatment of Egyptian Patients With Chronic Hepatitis C Genotype-4
IOSR Journal of Pharmacy (IOSRPHR)
The Effect of Pegylated Interferon-Alpha2b and Ribavirin Combination Therapy for Chronic Hepatitis C Infection in Elderly Patients
BMC Research Notes
Biochemistry
Medicine
Genetics
Molecular Biology
PGI18 Treatment of Chronic Hepatitis C Patients With Peginterferon Alfa-2a or Peginterferon Alfa-2b: A Cost-Effectiveness Analysis for the Portuguese NHS Setting
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pegylated Interferon and Ribavirin Combination Therapy for Chronic Hepatitis C Associated With Thyroid Dysfunction
Acta Hepatologica Japonica
Hepatology
Combination Therapy With Pegylated Interferon Plus Ribavirin in the Treatment of Hepatitis C Virus-Related Thrombocytopenia
Current Therapeutic Research
Pharmacology
Efficacy of Boceprevir, an NS3 Protease Inhibitor, in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naive Patients With Genotype 1 Hepatitis C Infection (SPRINT-1): An Open-Label, Randomised, Multicentre Phase 2 Trial
The Lancet
Medicine
Ledipasvir / Sofosbuvir for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Across Different Genotype 1 Clinical Subgroups
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness Analysis of Treatment With Peginterferon-Alfa-2a Versus Peginterferon-Alfa-2b for Patients With Chronic Hepatitis C Under the Public Payer Perspective in Brazil
Cost Effectiveness and Resource Allocation
Health Policy
